Exact Sciences, along with researchers at the Mayo Clinic, announced today that they have developed a blood test that correctly identified 95 percent of the cases of a common form of liver cancer (hepatocellular carcinoma or HCC).

“These results are further validation of our advanced DNA technology and our multi-biomarker approach for the detection of the deadliest forms of cancer,” Exact Sciences CEO Kevin Conroy said in a statement. “We look forward to advancing this important research in early stage cancer with Mayo Clinic.”

According to a release, the study, which included blood samples from 244 people, detected 93 percent of tumors at a curable stage.

Exact Sciences made the announcement at Digestive Disease Week in Washington, D.C.